- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02915757
Electrodermal Hyporeactivity And Depression (EUDOR-A)
Naturalistic Clinical Studies in Several Centres of Electrodermal Hyporeactivity in Adult Patients With Primary Depression
Visão geral do estudo
Descrição detalhada
This EUDOR-A study is a naturalistic, european and multicentric study. In France, patient's recruitment will be only conducted by investigators within the Department of Psychiatric Emergencies and Post Acute Care, University Hospital of Montpellier.
Over one year, 233 patients suffering from a major depressive episode with (n=70) and without any history of suicide attempt (n=163) will be recruited.
The maximum period of participation for a given patient will be 12 months with 2 phone assessments at 6 month and 12 month.
Inclusion visit: clinical and biological assessment and Edor test. Second and third visits at 6 and 12 month: Follow up visits in the department or interview by telephone in order to assess suicidal ideations or suicide attempts since the inclusion.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Montpellier, França, 34295
- Montpellier University Hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion criteria:
All subjects men and women will necessarily meet the following inclusion criteria:
- In- and outpatients, with a diagnosis of primary depression according to the International classification of Disease (ICD-10) should be included as a routine. That is, patients in a primary unipolar major episode or dysthymia or primary depression with a personality disorder or an anxiety disorder as secondary diagnoses and primary bipolar disorder in a non-hypomanic and non-manic phase are expected to be included.
- Age : 18 years or older
- written informed consent
- must belong to social safety system
- To be able to understand instructions for the EDOR Test, the aim and the methodology of the study.
Exclusion criteria:
- diagnosed or suspected dementia
- Acute known or suspected alcohol or other substance abuse. The condition of past substance abuse (i.e. alcohol abuse or dependance, drug abuse or dependance ) should be noted in the comment field of the EDOR Test routine and patient must have been abstinent for at least one year.
- Serious problems of hearing, the patient should not participate.
- Refusal of participation
- Subject deprived of liberty (by judicial or administrative decision)
- Subject protected by law.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Depressive patients
EDOR test on depressed patients with or without personal history of suicidal behavior
|
The ElectroDermal Orienting Reactivity (EDOR) specifically is optimized for the detection of electrodermal hyporeactivity. The EDOR investigation last about 30 min. The EDOR Test Data is sent immediately after each EDOR Test for each Test Person to a Company named EMOTRA for blind analyses. The EDOR Test Report may change the basis for the assessment and a new risk assessment may be needed to be done. Blood sample and clinical assessment |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Specificity and sensibility of the electrodermal hyporeactivity
Prazo: At 6 and 12 month
|
Correlation between the Edor Test results and suicidal behavior
|
At 6 and 12 month
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
Prazo: At 6 month
|
Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal
|
At 6 month
|
The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Columbia-Suicide Severity Rating Scale (C-SSRS)
Prazo: At 6 and 12 month
|
Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal
|
At 6 and 12 month
|
Electrodermal activity in depressive and suicidal patients with or without insomnia.
Prazo: At 6 and 12 month
|
Comparison of test result between patients with insomnia and patient without insomnia.
Insomnia will be evaluated with the "Insomnia severity index" (ISI).
|
At 6 and 12 month
|
Genetic vulnerability to suicidal behavior by polymorphism analysis in blood sample
Prazo: At the inclusion
|
To study the polymorphisms by blood sample analysis of the promotor of Spermidine/Spermine Acetyltransferase 1 (SAT1), Phenylethanolamine N-Methyltransferase (PNMT) and Noradrenalin Transporter (NAT).
between depressed patients with suicidal behavior and depressed patients without suicidal behavior.
|
At the inclusion
|
The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Risk Rescue Rating Scale (RRRS)
Prazo: At 6 and 12 month
|
Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal
|
At 6 and 12 month
|
The sensibility of the electrodermal hyporeactivity compared with the occurrence of the violent suicidal attempt measured by Beck Scale for Suicidal Intent (SIS).
Prazo: At 6 and 12 month
|
Comparison of test result between patients with history of violent suicidal attempt and patients with history of non violent suicidal
|
At 6 and 12 month
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- UF 9464
- 2014-A01310-47 (Outro identificador: Agence Nationale de sécurité des Médicaments)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em EDOR test
-
Istinye UniversityInscrevendo-se por conviteDerrame | Teleavaliação | O teste Timed Up & Go | Teste de levantar da cadeira de 30 segundosPeru
-
Assistance Publique - Hôpitaux de ParisDesconhecidoVentilação mecânicaFrança
-
Kenya Medical Research InstituteFoundation for Innovative New Diagnostics (FIND)Desconhecido
-
hearX GroupUniversity of PretoriaConcluído
-
Tel-Aviv Sourasky Medical CenterDesconhecidoPerda auditiva neurossensorial súbita
-
Drägerwerk AG & Co. KGaARescindido
-
University Hospital, BordeauxDesconhecido
-
PepsiCo Global R&DConcluído
-
AllerdermConcluídoDermatite de contatoDinamarca, Estados Unidos
-
Ufuk UniversityConcluído